1---2name: managing-childhood-obesity3description: Guides pediatric weight management with BMI percentile tracking and family-based interventions. Use when managing childhood obesity, tracking BMI percentiles, or implementing weight management plans.4---5
6# Managing Childhood Obesity
7
8Guides pediatric weight management using BMI percentile classification (CDC 2023 updated cutoffs), staged intervention intensity (Prevention Plus through Tertiary Care), comorbidity screening, motivational interviewing for family-based behavioral change, and pharmacotherapy/surgical referral criteria for adolescents.
9
10## Why This Skill Exists
11
12Childhood obesity affects approximately 20% of U.S. children ages 2-19. It is the strongest predictor of adult obesity and metabolic disease. The AAP 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity marked a paradigm shift — recommending early intensive treatment including pharmacotherapy and metabolic surgery for appropriate candidates rather than prolonged "watchful waiting." This skill implements the updated AAP framework with staged intervention intensity, mandatory comorbidity screening, and explicit criteria for escalation.
13
14---
15
16## Checkpoint A — Intake Verification
17
18### Required Intake Questions
191. What is the child's age, sex, current weight (kg), and height (cm)?
202. What is the calculated BMI and BMI percentile (or extended BMI if ≥ 95th percentile)?
213. What is the family history (obesity, T2DM, cardiovascular disease, obstructive sleep apnea)?
224. What is the child's dietary pattern (meals/day, fast food frequency, sugar-sweetened beverages, portion sizes)?
235. What is the child's physical activity level (minutes/day, screen time hours/day)?
246. What is the child's sleep duration and quality?
257. Does the child have symptoms of: acanthosis nigricans, snoring/apnea, hip/knee pain, headaches, menstrual irregularity?
268. What is the family's readiness for change (precontemplation, contemplation, preparation, action)?
279. Has the child experienced weight-related bullying or emotional distress?
28
29### Required Documents
30- Serial height/weight data with BMI trend
31- BMI plotted on CDC growth chart (ages 2-20)
32- Previous lab results (lipids, glucose, liver enzymes) if available
33- Sleep history or polysomnography results if applicable
34
35---
36
37## Step 1 — BMI Classification and Severity
38
39### BMI Percentile Categories (CDC, Ages 2-20)
40| Category | BMI Percentile |
41|----------|---------------|
42| Underweight | < 5th |
43| Healthy weight | 5th to < 85th |
44| Overweight | 85th to < 95th |
45| Obesity (Class I) | ≥ 95th to < 120% of 95th percentile |
46| Severe obesity (Class II) | ≥ 120% to < 140% of 95th percentile |
47| Severe obesity (Class III) | ≥ 140% of 95th percentile |
48
49### Extended BMI (%95th)
50- For children at or above the 95th percentile, express BMI as a percentage of the 95th percentile value for age/sex
51- This provides more granularity than raw percentile at the extreme end
52- Example: if 95th percentile BMI for a 10-year-old male is 24.0 and the patient's BMI is 30.0, extended BMI = (30.0 / 24.0) × 100 = 125% of 95th → Class II severe obesity
53
54---
55
56## Step 2 — Comorbidity Screening
57
58### Required Laboratory Screening (For BMI ≥ 85th Percentile)
59| Test | Purpose | Frequency |
60|------|---------|-----------|
61| Fasting lipid panel | Dyslipidemia | At initial evaluation, then per NHLBI guidelines |
62| Fasting glucose + HbA1c | Prediabetes/T2DM | ≥ 10 years old with BMI ≥ 85th + risk factors; or any with BMI ≥ 95th |
63| ALT | NAFLD screening | ≥ age 9-11; earlier if BMI ≥ 95th |
64| Blood pressure | Hypertension | Every visit; confirm with ambulatory monitoring if elevated |
65
66### Clinical Comorbidity Assessment
67- **Orthopedic**: slipped capital femoral epiphysis (SCFE — hip/knee/groin pain with limping), Blount disease (tibial bowing)
68- **Pulmonary**: obstructive sleep apnea (snoring, daytime somnolence, morning headaches) — polysomnography if symptomatic
69- **Endocrine**: acanthosis nigricans (insulin resistance marker), polycystic ovarian syndrome (PCOS) in females with irregular menses
70- **Psychological**: depression screening (PHQ-A), anxiety, disordered eating behaviors (binge eating), bullying assessment
71- **Dermatologic**: intertrigo, acanthosis nigricans distribution and severity
72
73---
74
75## Step 3 — Staged Intervention Intensity (AAP 2023)
76
77### Stage 1: Prevention Plus (All BMI ≥ 85th)
78- ≥ 5 servings fruits/vegetables daily
79- Minimize or eliminate sugar-sweetened beverages
80- Limit screen time to ≤ 2 hours/day recreational (0 for < 2 years)
81- ≥ 60 minutes moderate-to-vigorous physical activity daily
82- Family meals at table; no eating in front of screens
83- Adequate sleep for age
84
85### Stage 2: Structured Weight Management (No Improvement After 3-6 Months of Stage 1)
86- Structured meal plan with dietitian involvement
87- Detailed food and activity logging
88- Monthly office visits for weight tracking and behavioral support
89- Targeted behavioral goals with family accountability
90
91### Stage 3: Comprehensive Multidisciplinary Intervention
92- Intensive behavioral therapy (≥ 26 contact hours over 3-12 months)
93- Multidisciplinary team: pediatrician, dietitian, behavioral health, exercise specialist
94- This is the core treatment recommended by AAP 2023 for children ≥ 6 with obesity
95- Where available, Intensive Health Behavior and Lifestyle Treatment (IHBLT) programs
96
97### Stage 4: Tertiary Care Intervention
98- **Pharmacotherapy** (age ≥ 12 with obesity, or ≥ 8 per AAP 2023):
99 - GLP-1 receptor agonists (liraglutide FDA-approved ≥ 12 years; semaglutide ≥ 12 years)
100 - Orlistat (≥ 12 years): limited efficacy, GI side effects
101 - Phentermine/topiramate: off-label in adolescents, limited data
102 - Setmelanotide: for specific genetic obesity syndromes (MC4R pathway)
103- **Metabolic and bariatric surgery** (age ≥ 13 with Class II obesity + comorbidity OR Class III obesity):
104 - Roux-en-Y gastric bypass or vertical sleeve gastrectomy
105 - Requires multidisciplinary evaluation, psychological clearance, demonstrated adherence to lifestyle changes
106 - Refer to accredited pediatric bariatric center
107
108---
109
110## Step 4 — Motivational Interviewing and Goal Setting
111
112### Motivational Interviewing Framework (OARS)
113- **Open-ended questions**: "What concerns do you have about your child's weight?"
114- **Affirmations**: "You're doing a great job by coming to talk about this."
115- **Reflective listening**: "It sounds like it's been hard to find time for physical activity."
116- **Summarizing**: "So you're thinking about reducing soda and adding a family walk after dinner."
117
118### SMART Goal Setting (1-2 Goals Per Visit)
119- Specific, Measurable, Achievable, Relevant, Time-bound
120- Example: "Reduce sugar-sweetened beverages from 3 cans/day to 1 can/day over the next 4 weeks"
121- Document goals in chart and review at each follow-up
122
123### Weight Trajectory Goals (Not Absolute Weight Loss)
124| Age / Severity | Goal |
125|----------------|------|
126| 2-5 years, overweight | Weight maintenance (BMI improves as height increases) |
127| 2-5 years, obese | Weight maintenance; gradual weight loss if severe |
128| 6-11 years, overweight | Weight maintenance |
129| 6-11 years, obese | Gradual weight loss (max 1 lb/month) |
130| 12-18 years, overweight | Weight maintenance to gradual loss |
131| 12-18 years, obese | Weight loss up to 2 lb/week with medical supervision |
132
133---
134
135## Step 5 — Follow-Up and Escalation
136
137### Visit Frequency
138- Stage 1: every 3-6 months
139- Stage 2: monthly
140- Stage 3: weekly to biweekly during intensive phase
141- Stage 4: per specialty protocol
142
143### Escalation Triggers
144- No BMI improvement after 3-6 months at current stage → escalate to next stage
145- Development of new comorbidity (T2DM, hypertension, NAFLD) → accelerate staging
146- Rapid BMI increase (crossing percentile lines upward) → do not wait standard interval
147- Severe obesity (Class II-III) in adolescent → offer pharmacotherapy and Stage 3 simultaneously (AAP 2023)
148
149---
150
151## Checkpoint B — Obesity Management Review
152
153- [ ] BMI calculated with percentile and extended BMI (if ≥ 95th) documented
154- [ ] BMI plotted on CDC growth chart with trend visible
155- [ ] Comorbidity screening labs ordered or reviewed (lipids, glucose/HbA1c, ALT)
156- [ ] Blood pressure measured and classified
157- [ ] Dietary assessment documented with specific targets identified
158- [ ] Physical activity and screen time assessed
159- [ ] Sleep duration assessed
160- [ ] Psychological screening completed (depression, bullying, disordered eating)
161- [ ] Stage of intervention assigned with rationale
162- [ ] SMART goals documented for this visit
163- [ ] Follow-up visit scheduled at appropriate interval for stage
164- [ ] All [VERIFY] flags resolved or escalated
165
166---
167
168## Quality Audit
169
170| Item | Requirement | Pass? |
171|------|-------------|-------|
172| BMI classification | Correct category with extended BMI if ≥ 95th | |
173| Growth chart | BMI plotted on CDC chart with trend over ≥ 2 visits | |
174| Lab screening | Lipids, glucose/HbA1c, ALT per age and BMI criteria | |
175| Comorbidity assessment | OSA, orthopedic, endocrine, psychological all screened | |
176| Stage assignment | Intervention intensity matches obesity severity and duration | |
177| Family engagement | Motivational interviewing approach documented | |
178| Goal specificity | SMART goals documented (not vague "eat better") | |
179| Weight goal | Age-appropriate weight trajectory goal stated | |
180| Escalation criteria | Timeline for stepping up intervention documented | |
181| No unexplained [VERIFY] tags | All flagged items resolved or escalated | |
182
183---
184
185## Guidelines
186
187- Follow AAP 2023 Clinical Practice Guideline for Evaluation and Treatment of Children and Adolescents with Obesity
188- Use CDC BMI-for-age growth charts (ages 2-20) with extended BMI percentiles for severe obesity classification
189- Apply Expert Committee (Barlow 2007) staged approach for intervention intensity
190- Follow NHLBI Integrated Guidelines for Cardiovascular Health (lipid screening schedule)
191- Follow ADA Standards of Care for T2DM screening criteria in youth
192- Follow NASPGHAN guidelines for NAFLD screening in children
193- GLP-1 RA therapy: follow FDA-approved labeling (liraglutide and semaglutide ≥ 12 years)
194- Metabolic surgery: follow ASMBS pediatric guidelines; accredited center required
195- Do not use BMI in children under 2 — use weight-for-length on WHO growth chart
196- Avoid stigmatizing language: use "has obesity" not "is obese"; use "unhealthy weight" not "fat"
197- This skill produces clinical documentation; it does not replace clinical judgment